title: Nontuberculous mycobacterial infection in children: a prospective national study.
abstract: BACKGROUND
  The epidemiology and management of nontuberculous mycobacterial (NTM) infection in Australian children is unknown.
  
  
  METHODS
  From July 2004 to June 2007, clinicians identified children with NTM infection as part of a nationwide active surveillance network. Following notification, detailed data were collected.
  
  
  RESULTS
  From 192 reports, data were received on 153 cases (response rate: 79.7%). Of these, 102 met inclusion criteria. The median age was 2.9 years. Predisposing conditions were infrequent and included chronic respiratory disease (n = 12) and immunosuppression (n = 6). Lymphadenitis was the most frequent presentation (n = 68) with pulmonary and disseminated disease infrequent (n = 14 and 3, respectively). NTM was isolated in 68 cases with Mycobacterium avium-intracellulare complex most frequently isolated (33/68; 48.5%). Surgery was performed in 78 cases and 42 children were treated with antimycobacterial therapy. Twenty-five subjects received surgery and antimycobacterial therapy. Follow-up data were available for 77 children with recurrence observed in 18 cases. Complete excision was associated with a higher rate of treatment success when compared with all other therapies (OR: 9.48 [95% CI: 2.00-44.97], P = 0.001). Mycobacterium lentiflavum infection accounted for 4.4% of culture confirmed cases and had a lower rate of treatment success than other species (0% vs. 78.2%; P = 0.016).
  
  
  CONCLUSIONS
  The incidence of NTM infection in Australian children is 0.84 of 100,000 (95% CI: 0.68-1.02). Infection occurs most often in young children without predisposing conditions. Despite therapy, there was recurrence in 23.4% of cases.
authors.affiliation: Department of Immunology and Infectious Diseases, Sydney Children's Hospital, New South Wales, Australia.
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Blyth
authors.forename: Emma J
authors.initials: EJ
authors.lastname: Best
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Jones
authors.forename: Clare
authors.initials: C
authors.lastname: Nourse
authors.forename: Paul N
authors.initials: PN
authors.lastname: Goldwater
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Daley
authors.forename: David
authors.initials: D
authors.lastname: Burgner
authors.forename: Guy
authors.initials: G
authors.lastname: Henry
authors.forename: Pamela
authors.initials: P
authors.lastname: Palasanthiran
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000995:Antitubercular Agents / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D009161:Mycobacterium / Q000145:classification* / Q000302:isolation & purification*; D009164:Mycobacterium Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology* / Q000601:surgery; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000995:Antitubercular Agents